{"protocolSection":{"identificationModule":{"nctId":"NCT01662440","orgStudyIdInfo":{"id":"V49_23"},"secondaryIdInfos":[{"id":"2011-005173-23","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Novartis","class":"INDUSTRY"},"briefTitle":"Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects","officialTitle":"A Phase III, Multicenter, Observer-blind, Safety and Immunogenicity Study of Rabies Vaccine and Japanese Encephalitis Vaccine Administered Concomitantly and/or Separately According to 1 of 2 Different Preexposure Prophylaxis Schedules to Healthy Adult Subjects."},"statusModule":{"statusVerifiedDate":"2014-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2012-08"},"primaryCompletionDateStruct":{"date":"2012-12","type":"ACTUAL"},"completionDateStruct":{"date":"2013-10","type":"ACTUAL"},"studyFirstSubmitDate":"2012-08-02","studyFirstSubmitQcDate":"2012-08-07","studyFirstPostDateStruct":{"date":"2012-08-10","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-10-06","resultsFirstSubmitQcDate":"2014-12-02","resultsFirstPostDateStruct":{"date":"2014-12-08","type":"ESTIMATED"},"dispFirstSubmitDate":"2013-04-23","dispFirstSubmitQcDate":"2013-04-23","dispFirstPostDateStruct":{"date":"2013-05-01","type":"ESTIMATED"},"lastUpdateSubmitDate":"2014-12-02","lastUpdatePostDateStruct":{"date":"2014-12-08","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Novartis Vaccines","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"Establish non-inferiority of the immune response and evaluate the safety and tolerability of Rabies and Japanese Encephalitis (JE) vaccines given concomitantly or alone and according to either of 2 schedules for preexposure prophylaxis."},"conditionsModule":{"conditions":["Rabies","Japanese Encephalitis"],"keywords":["Rabies","JE","accelerated schedule"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":661,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"R/JE - Conv","type":"ACTIVE_COMPARATOR","description":"Subjects received Rabies and Japanese Encephalitis (JE) vaccines following the conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg; and JE vaccination on day 1 and 29, and placebo on day 8 in the left arm.","interventionNames":["Biological: Rabies","Biological: Japanese Encephalitis","Other: Placebo"]},{"label":"R/JE - Acc","type":"EXPERIMENTAL","description":"Subjects received Rabies and JE vaccines following the accelerated schedule, ie, Rabies vaccination on days 1, 4, and 8, and placebo on day 29 in the right arm or leg; and JE vaccination on days 1 and 8, and placebo on day 29 in the left arm.","interventionNames":["Biological: Rabies","Biological: Japanese Encephalitis","Other: Placebo"]},{"label":"R - Conv","type":"ACTIVE_COMPARATOR","description":"Subjects received Rabies vaccine following the conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg; and placebo on days 1, 8 and 29 in the left arm.","interventionNames":["Biological: Rabies","Other: Placebo"]},{"label":"JE - Conv","type":"ACTIVE_COMPARATOR","description":"Subjects received JE vaccine following the conventional schedule, ie, placebo on days 1, 4, 8 and 29 in the right arm or leg; and JE vaccination on days 1 and 29 and placebo injection on day 8 in the left arm.","interventionNames":["Biological: Japanese Encephalitis","Other: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Rabies","description":"Subjects received three doses of Rabies, whole virus vaccine (inactivated, Germany).","armGroupLabels":["R - Conv","R/JE - Acc","R/JE - Conv"]},{"type":"BIOLOGICAL","name":"Japanese Encephalitis","description":"Subjects received two doses of Japanese Encephalitis vaccine.","armGroupLabels":["JE - Conv","R/JE - Acc","R/JE - Conv"]},{"type":"OTHER","name":"Placebo","description":"Subjects received either two, three, four or five doses of normal saline, 0.9% w/v sodium chloride depending on the vaccine group.","armGroupLabels":["JE - Conv","R - Conv","R/JE - Acc","R/JE - Conv"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentages of Subjects With RVNA Concentrations ≥0.5 IU/mL At 7 Days After Last Active Vaccination","description":"Immune response was measured as the percentage of subjects with rabies virus neutralizing antibody (RVNA) concentrations ≥0.5 IU/mL, evaluated using the rapid fluorescent focus inhibition test at day 7 after last active vaccination, i.e. the third out of four vaccinations given in the accelerated Rabies vaccine schedule and the fourth out of four vaccinations given in the conventional Rabies vaccine schedule.\n\nAs per study design, this primary immunogenicity outcome measure aimed to demonstrate non-inferiority of R/JE - Acc Vs R - Conv.","timeFrame":"Day 7 after last active vaccination (day 15 - group that received accelerated schedule, day 36 - group that received conventional schedule)"},{"measure":"Percentages of Subjects With PRNT50 Titer ≥1:10 At 28 Days After Last Active Vaccination","description":"Immune response was measured as the percentages of subjects with a titer of ≥1:10 in a 50% plaque reduction neutralization test (PRNT50) 28 days after last active vaccination, ie, the second out of three vaccinations given in the accelerated JE vaccine schedule and the third out of three vaccinations given in the conventional JE vaccine schedule.\n\nAs per study design, this primary immunogenicity outcome measure aimed to demonstrate non-inferiority of R/JE - Acc Vs JE - Conv.","timeFrame":"Day 28 after last active vaccination (day 36 - group that received accelerated schedule, day 57 - group that received conventional schedule)"}],"secondaryOutcomes":[{"measure":"RVNA Geometric Mean Concentrations (GMCs) At 28 Days After Last Active Vaccination","description":"Immune response was measured as the RVNA GMCs 28 days after last active vaccination, ie, day 57 for all groups that received the conventional schedule.\n\nData were adjusted using ANOVA model, as per protocol specification.","timeFrame":"Day 57 (28 days after last active vaccination)"},{"measure":"PRNT50 Geometric Mean Titers (GMTs) At 28 Days After Last Active Vaccination","description":"Immune response was measured as the PRNT50 GMTs 28 days after last active vaccination, ie, day 57 for all groups that received the conventional schedule.\n\nData were adjusted using ANOVA model, as per protocol specifications.","timeFrame":"Day 57 (28 days after last active vaccination)"},{"measure":"Percentages of Subjects With RVNA Concentrations ≥0.5 IU/mL At 28 Days After Last Active Vaccination","description":"Immune response was measured as the percentages of subjects with RVNA concentration ≥0.5 IU/mL 28 days after last active vaccination, ie, day 36 for the group that received the accelerated schedule and day 57 for the group that received the conventional schedule.\n\nAs per study design, this secondary immunogenicity outcome measure aimed to demonstrate non-inferiority of R/JE - Acc Vs R - Conv.","timeFrame":"Day 36 and day 57 (28 days after last active vaccination)"},{"measure":"Percentage of Subjects With PRNT50 Titer ≥1:10 At 7 Days After Last Active Vaccination","description":"Immune response was measured as the percentage of subjects with PRNT50 titer of ≥1:10 7 days after last active vaccination, ie, day 15 for the group that received the accelerated schedule and day 36 for the group that received the conventional schedule.\n\nAs per study design, this secondary immunogenicity outcome measure aimed to demonstrate non-inferiority of R/JE - Acc Vs JE - Conv.","timeFrame":"Day 15 and day 36 (28 after last active vaccination)"},{"measure":"Kinetics of Rabies Immune Response Measured as Percentage of Subjects With RVNA Concentration ≥0.5 IU/mL","description":"To evaluate the kinetics of antibody response to Rabies vaccine, the immunogenicity was measured as the percentage of subjects with RVNA concentrations ≥0.5 IU/mL on days 1, 8, 15, 36, 57, 91, 181, and 366.","timeFrame":"Day 1, 8, 15, 36, 57, 91, 181 and Day 366"},{"measure":"Kinetics of Rabies Immune Response Measured as the RVNA GMCs","description":"To evaluate the kinetics of antibody response to Rabies vaccine, the immunogenicity was measured as the RVNA GMCs on days 1, 8, 15, 36, 57, 91, 181, and 366.","timeFrame":"Day 1, 8, 15, 36, 57, 91, 181, and 366"},{"measure":"Kinetics of JE Immune Response Measured as Percentage of Subjects With PRNT50 Titers ≥1:10","description":"To evaluate the kinetics of antibody response to JE vaccine, the immunogenicity was measured as the percentage of subjects with PRNT50 titer ≥1:10 on days 1, 15, 22, 36, 57, 91, 181, and 366 (group that received JE vaccine as an accelerated schedule) and days 1, 36, 57, 181, and 366 (group that received JE vaccine as a conventional schedule).","timeFrame":"Days 1, 15, 22, 36, 57, 91, 181 and 366"},{"measure":"Kinetics of JE Immune Response Measured as PRNT50 GMTs","description":"To evaluate the kinetics of antibody response to JE vaccine, the immunogenicity was measured as the PRNT50 GMTs on days 1, 15, 22, 36, 57, 91, 181, and 366 (group that received JE vaccine as an accelerated schedule) and days 1, 36, 57, 181, and 366 (group that received JE vaccine as a conventional schedule).","timeFrame":"Day 1, 15, 22, 36, 57, 91, 181, and 366 (accelerated schedule) and day 1, 36, 57, 181, and 366 (conventional schedule)"},{"measure":"Number of Subjects Who Reported Solicited Local Adverse Events After Each Rabies Vaccination","description":"Safety was assessed as the number of subjects who reported solicited local adverse events (AEs) after each rabies vaccination given according to accelerated or conventional schedule as follows: from day 1 through day 7 (vaccination on day 1; all Rabies groups), day 4 through day 10 (vaccination on day 4; in R/JE - Acc group only), day 8 through day 14 (vaccination on day 8; all Rabies groups), or day 29 through day 35 (vaccination on day 29; R/JE - Conv and R - Conv groups).","timeFrame":"Day 1 through day 7 after each vaccination (on day 1, 4, 8 and 29)"},{"measure":"Number of Subjects Who Reported Solicited Local AEs After Each JE Vaccination","description":"Safety was assessed as the number of subjects who reported solicited local AEs after each JE vaccination given according to accelerated or conventional schedule as follow: from day 1 through day 7 (vaccination on day 1; all JE groups), day 8 through day 14 (vaccination on day 8; R/JE - Acc group only), or day 29 through day 35 (vaccination on day 29; R/JE - Con and JE - Conv groups).","timeFrame":"Day 1 through day 7 after each vaccination (on day 1, 8 and 29)"},{"measure":"Number of Subjects Who Reported Solicited Local AEs After Each Placebo Injection","description":"Safety was assessed as the number of subjects who reported solicited local AEs after each placebo injection given according to accelerated and conventional schedule as follow: from day 1 through day 7 (injection on day 1; R - Conv and JE - Conv groups), day 4 through day 10 (injection on day 4; in R/JE - Conv, R - Conv and JE - Conv groups), day 8 through day 14 (injection on day 8; in R/JE - Conv, R - Conv and JE - Conv groups), and day 29 through day 35 (injection on day 29; R/JE - Acc, R - Con and JE - Conv groups).","timeFrame":"Day 1 through day 7 after each injection (day 1, 4, 8 and 29)"},{"measure":"Number of Subjects Who Reported Solicited Systemic AEs and Other Indicators of Reactogenicity After Each Vaccination","description":"Safety was assessed as the number of subjects who reported solicited systemic AEs and other indicators of reactogenicity after each vaccination given according to accelerated and conventional schedule.","timeFrame":"Day 1 through day 7 after each vaccination (day 1, 4, 8 and 29)"},{"measure":"Numbers of Subjects Reporting Unsolicited AEs After Any Vaccination From Day 1 Through Day 57","description":"Safety was assessed as the number of subjects who reported unsolicited AEs after any vaccination given according to accelerated and conventional schedule.","timeFrame":"Day 1 through Day 57"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Males and females between 18 and 65 years of age (inclusive).\n2. Subjects who have given written consent.\n3. Individuals in good health as per investigator judgement.\n\nExclusion Criteria:\n\n1. If female, pregnancy or unwillingness to practice acceptable contraception.\n2. If female, pregnant or breast-feeding or any positive/indeterminate pregnancy test.\n3. Contraindication or precaution against Rabies and Japanese Encephalitis vaccination.\n4. Unable to comprehend and to follow all required study procedures for the whole period of the study.\n5. Participating in any other clinical trial 30 days prior to first study visit.\n6. History of previous rabies/rabies immunoglobulin and/or Japanese Encephalitis immunization.\n7. Receiving or planning to receive anti-malarial medications (e.g. Mefloquine) 14 days prior to Day 1 vaccination through Day 43.\n8. Received any other vaccines within 2 weeks prior to enrollment in this study or plan to receive any vaccine within 4 weeks from the study vaccines.\n9. Ever received blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation in the past 12 weeks.\n10. Individuals who are part of study personnel or close family members conducting this study.\n11. Body temperature ≥38 degrees Celsius (≥ 100.4° F) within 3 days of intended study vaccination.\n12. Plans to travel within the next year to areas where Rabies and/or Japanese Encephalitis vaccine may be considered or offered. This includes but is not limited to India, Asia, Pacific-Rim, African countries.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Novartis Vaccines and Diagnostics","affiliation":"Novartis Vaccines","role":"STUDY_CHAIR"}],"locations":[{"facility":"Institute of Specific Prophylaxis and Tropical Medicine Center for Pathophysiology, Infectious Diseases and Immunology Medical University of Vienna","city":"Kinderspitalgasse 15","state":"State of Vienna","zip":"A-1090","country":"Austria"},{"facility":"Bernhard Nocht Institute for Tropical Medicine","city":"Bernhard-Nocht-Strasse 74","state":"Free and Hanseatic City of Hamburg","zip":"D-20359","country":"Germany"},{"facility":"The University of Zurich","city":"Rämistrasse 71","state":"Canton of Zurich","zip":"CH-8006","country":"Switzerland"}]},"referencesModule":{"references":[{"pmid":"26994987","type":"DERIVED","citation":"Cramer JP, Jelinek T, Paulke-Korinek M, Reisinger EC, Dieckmann S, Alberer M, Buhler S, Bosse D, Meyer S, Fragapane E, Costantini M, Pellegrini M, Lattanzi M, Dovali C. One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary series. J Travel Med. 2016 Mar 19;23(3):taw011. doi: 10.1093/jtm/taw011. Print 2016 Mar."},{"pmid":"26005163","type":"DERIVED","citation":"Jelinek T, Cramer JP, Dieckmann S, Hatz C, Paulke-Korinek M, Alberer M, Reisinger EC, Costantini M, Gniel D, Bosse D, Lattanzi M. Evaluation of rabies immunogenicity and tolerability following a purified chick embryo cell rabies vaccine administered concomitantly with a Japanese encephalitis vaccine. Travel Med Infect Dis. 2015 May-Jun;13(3):241-50. doi: 10.1016/j.tmaid.2015.05.008. Epub 2015 May 18."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"All subjects were included in the trial.","recruitmentDetails":"Subjects were enrolled from five sites in Germany, one site in Austria, and one site in Switzerland.","groups":[{"id":"FG000","title":"R/JE - Conv","description":"Subjects received Rabies and Japanese Encephalitis (JE) vaccines, conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg; and JE vaccination on day 1 and 29, and placebo on day 8 in the left arm."},{"id":"FG001","title":"R/JE - Acc","description":"Subjects received Rabies and JE vaccines, accelerated schedule, ie, Rabies vaccination on days 1, 4, and 8, and placebo on day 29 in the right arm or leg; and JE vaccination on days 1 and 8, and placebo on day 29 in the left arm."},{"id":"FG002","title":"R - Conv","description":"Subjects received Rabies vaccine, conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg; and placebo on days 1, 8 and 29 in the left arm."},{"id":"FG003","title":"JE - Conv","description":"Subjects received JE vaccine, conventional schedule, ie, placebo on days 1, 4, 8 and 29 in the right arm or leg; and JE vaccination on days 1 and 29 and placebo injection on day 8 in the left arm."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"167"},{"groupId":"FG001","numSubjects":"217"},{"groupId":"FG002","numSubjects":"221"},{"groupId":"FG003","numSubjects":"56"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"158"},{"groupId":"FG001","numSubjects":"211"},{"groupId":"FG002","numSubjects":"215"},{"groupId":"FG003","numSubjects":"52"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"4"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Subject moved to another country.","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"R/JE - Conv","description":"Subjects received Rabies and JE vaccines, conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg; and JE vaccination on day 1 and 29, and placebo on day 8 in the left arm."},{"id":"BG001","title":"R/JE - Acc","description":"Subjects received Rabies and JE vaccines, accelerated schedule, ie, Rabies vaccination on days 1, 4, and 8, and placebo on day 29 in the right arm or leg; and JE vaccination on days 1 and 8, and placebo on day 29 in the left arm."},{"id":"BG002","title":"R - Conv","description":"Subjects received Rabies vaccine, conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg; and placebo on days 1, 8 and 29 in the left arm."},{"id":"BG003","title":"JE - Conv","description":"Subjects received JE vaccine, conventional schedule, ie, placebo on days 1, 4, 8 and 29 in the right arm or leg; and JE vaccination on days 1 and 29 and placebo injection on day 8 in the left arm."},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"167"},{"groupId":"BG001","value":"217"},{"groupId":"BG002","value":"221"},{"groupId":"BG003","value":"56"},{"groupId":"BG004","value":"661"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"year","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"37.3","spread":"13.4"},{"groupId":"BG001","value":"36.8","spread":"12.7"},{"groupId":"BG002","value":"35.7","spread":"12.6"},{"groupId":"BG003","value":"38.8","spread":"13.3"},{"groupId":"BG004","value":"36.7","spread":"12.9"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"76"},{"groupId":"BG001","value":"128"},{"groupId":"BG002","value":"125"},{"groupId":"BG003","value":"30"},{"groupId":"BG004","value":"359"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"91"},{"groupId":"BG001","value":"89"},{"groupId":"BG002","value":"96"},{"groupId":"BG003","value":"26"},{"groupId":"BG004","value":"302"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentages of Subjects With RVNA Concentrations ≥0.5 IU/mL At 7 Days After Last Active Vaccination","description":"Immune response was measured as the percentage of subjects with rabies virus neutralizing antibody (RVNA) concentrations ≥0.5 IU/mL, evaluated using the rapid fluorescent focus inhibition test at day 7 after last active vaccination, i.e. the third out of four vaccinations given in the accelerated Rabies vaccine schedule and the fourth out of four vaccinations given in the conventional Rabies vaccine schedule.\n\nAs per study design, this primary immunogenicity outcome measure aimed to demonstrate non-inferiority of R/JE - Acc Vs R - Conv.","populationDescription":"Analysis was done on the per-protocol (PP) dataset, ie, the subjects who received the vaccine correctly, provided evaluable serum samples at the relevant time points, and had no major protocol violations as defined prior to unblinding.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentages of subjects","timeFrame":"Day 7 after last active vaccination (day 15 - group that received accelerated schedule, day 36 - group that received conventional schedule)","groups":[{"id":"OG000","title":"R/JE - Acc","description":"Subjects received Rabies and JE vaccines, accelerated schedule, ie, Rabies vaccination on days 1, 4, and 8, and placebo on day 29 in the right arm or leg, and JE vaccination on days 1 and 8, and placebo on day 29 in the left arm."},{"id":"OG001","title":"R - Conv","description":"Subjects received Rabies vaccine, conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg, and placebo on days 1, 8 and 29 in the left arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"207"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"97","upperLimit":"100"},{"groupId":"OG001","value":"100","lowerLimit":"97","upperLimit":"100"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"To establish non-inferiority of the immune response of Rabies vaccine (administered concomitantly with JE vaccine) accelerated schedule as compared to conventional schedule at 7 days after last active vaccination.","testedNonInferiority":true,"nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"The immune response of accelerated schedule of the Rabies vaccine considered non-inferior to the conventional schedule if the lower bound of the two-sided 97.5% Confidence Intervals (CI) of the difference in the percentages of subjects with RVNA titer ≥0.5 IU/mL measured 7 days after last active vaccination is greater than -5.","paramType":"Difference in percentages of subjects","paramValue":"0","ciPctValue":"97.5","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.8","ciUpperLimit":"2.8"}]},{"type":"PRIMARY","title":"Percentages of Subjects With PRNT50 Titer ≥1:10 At 28 Days After Last Active Vaccination","description":"Immune response was measured as the percentages of subjects with a titer of ≥1:10 in a 50% plaque reduction neutralization test (PRNT50) 28 days after last active vaccination, ie, the second out of three vaccinations given in the accelerated JE vaccine schedule and the third out of three vaccinations given in the conventional JE vaccine schedule.\n\nAs per study design, this primary immunogenicity outcome measure aimed to demonstrate non-inferiority of R/JE - Acc Vs JE - Conv.","populationDescription":"Analysis was done on the PP dataset.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentages of subjects","timeFrame":"Day 28 after last active vaccination (day 36 - group that received accelerated schedule, day 57 - group that received conventional schedule)","groups":[{"id":"OG000","title":"R/JE - Acc","description":"Subjects received Rabies and JE vaccines, accelerated schedule, ie, Rabies vaccination on days 1, 4, and 8, and placebo on day 29 in the right arm or leg, and JE vaccination on days 1 and 8, and placebo on day 29 in the left arm."},{"id":"OG001","title":"JE - Conv","description":"Subjects received JE vaccine, conventional schedule, ie, placebo on days 1, 4, 8 and 29 in the right arm or leg, and JE vaccination on days 1 and 29 and placebo injection on day 8 in the left arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"49"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99","lowerLimit":"96","upperLimit":"100"},{"groupId":"OG001","value":"100","lowerLimit":"93","upperLimit":"100"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Non-inferiority of the immune response of JE vaccine (administered concomitantly with Rabies vaccine) accelerated schedule as compared to conventional schedule at 28 day after last active vaccination","testedNonInferiority":true,"nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"The immune response of accelerated schedule of the JE vaccine is considered non-inferior to the conventional schedule if the lower bound of the two-sided 97.5% CI of the difference in the percentages of subjects with PRNT50 titer ≥1:10 measured 28 days after last active vaccination is greater than -10.","paramType":"Difference in percentages of subjects","paramValue":"-1","ciPctValue":"97.5","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.8","ciUpperLimit":"7.9"}]},{"type":"SECONDARY","title":"RVNA Geometric Mean Concentrations (GMCs) At 28 Days After Last Active Vaccination","description":"Immune response was measured as the RVNA GMCs 28 days after last active vaccination, ie, day 57 for all groups that received the conventional schedule.\n\nData were adjusted using ANOVA model, as per protocol specification.","populationDescription":"Analysis was done on the PP dataset.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"IU/mL","timeFrame":"Day 57 (28 days after last active vaccination)","groups":[{"id":"OG000","title":"R/JE - Conv","description":"Subjects received Rabies and JE vaccines, conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg, and JE vaccination on day 1 and 29, and placebo on day 8 in the left arm."},{"id":"OG001","title":"R - Conv","description":"Subjects received Rabies vaccine, conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg, and placebo on days 1, 8 and 29 in the left arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"204"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","lowerLimit":"9","upperLimit":"12"},{"groupId":"OG001","value":"9.9","lowerLimit":"8.57","upperLimit":"11"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Non-inferiority of the immune response of Rabies vaccine (administered concomitantly with JE vaccine) as compared to Rabies vaccines (administered alone) as given according to conventional schedule at 28day after last active vaccination","testedNonInferiority":true,"nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"The conventional schedule of Rabies vaccine co-administered with JE vaccine considered non inferior to the conventional schedule of Rabies vaccine administered alone if the lower bound of the two-sided 95% CI of the ratio of GMCs measured 28 days after last active vaccination is greater than 0.667.","paramType":"Between groups ratio of GMCs","paramValue":"1.07","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.86","ciUpperLimit":"1.32"}]},{"type":"SECONDARY","title":"PRNT50 Geometric Mean Titers (GMTs) At 28 Days After Last Active Vaccination","description":"Immune response was measured as the PRNT50 GMTs 28 days after last active vaccination, ie, day 57 for all groups that received the conventional schedule.\n\nData were adjusted using ANOVA model, as per protocol specifications.","populationDescription":"Analysis was done on the PP dataset.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers","timeFrame":"Day 57 (28 days after last active vaccination)","groups":[{"id":"OG000","title":"R/JE - Conv","description":"Subjects received Rabies and JE vaccines, conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg, and JE vaccination on day 1 and 29, and placebo on day 8 in the left arm."},{"id":"OG001","title":"JE - Conv","description":"Subjects received JE vaccine, conventional schedule, i.e. placebo on days 1, 4, 8 and 29 in the right arm or leg; and JE vaccination on days 1 and 29 and placebo injection on day 8 in the left arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"49"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"291","lowerLimit":"256","upperLimit":"331"},{"groupId":"OG001","value":"331","lowerLimit":"265","upperLimit":"415"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Non-inferiority of the immune response of JE vaccine (administered concomitantly with Rabies vaccine) as compared to JE vaccine (administered alone) as given according to conventional schedule at day 28 after last active vaccination.","testedNonInferiority":true,"nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"The conventional schedule of JE vaccine co-administered with Rabies vaccine considered non inferior to the conventional schedule of JE vaccine administered alone if the lower bound of the two-sided 95% CI of the ratio of GMTs measured 28 days after last active vaccination is greater than 0.5.","paramType":"Ratio of GMTs","paramValue":"0.88","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.68","ciUpperLimit":"1.13"}]},{"type":"SECONDARY","title":"Percentages of Subjects With RVNA Concentrations ≥0.5 IU/mL At 28 Days After Last Active Vaccination","description":"Immune response was measured as the percentages of subjects with RVNA concentration ≥0.5 IU/mL 28 days after last active vaccination, ie, day 36 for the group that received the accelerated schedule and day 57 for the group that received the conventional schedule.\n\nAs per study design, this secondary immunogenicity outcome measure aimed to demonstrate non-inferiority of R/JE - Acc Vs R - Conv.","populationDescription":"Analysis was done on the PP set.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentages of subjects","timeFrame":"Day 36 and day 57 (28 days after last active vaccination)","groups":[{"id":"OG000","title":"R/JE - Acc","description":"Subjects received Rabies and JE vaccines, accelerated schedule, ie, Rabies vaccination on days 1, 4, and 8, and placebo on day 29 in the right arm or leg, and JE vaccination on days 1 and 8, and placebo on day 29 in the left arm."},{"id":"OG001","title":"R - Conv","description":"Subjects received Rabies vaccine, conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg, and placebo on days 1, 8 and 29 in the left arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"206"},{"groupId":"OG001","value":"204"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99","lowerLimit":"96","upperLimit":"100"},{"groupId":"OG001","value":"100","lowerLimit":"97","upperLimit":"100"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Non-inferiority of the Rabies immune response (administered concomitantly with JE vaccine) as given according to an accelerated schedule as compared Rabies vaccine (administered alone) as given to a conventional schedule at day 28 after last active vaccination","testedNonInferiority":true,"nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"The immune response of accelerated schedule of the Rabies vaccine is considered non-inferior to the Rabies vaccine conventional schedule if the lower bound of the two-sided 95% CI of the difference in the percentages of subjects with RVNA titer ≥0.5 IU/mL measured 28 days after last active vaccine administration is greater than -5.","paramType":"Difference in percentages of subjects","paramValue":"-1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.8","ciUpperLimit":"1.4"}]},{"type":"SECONDARY","title":"Percentage of Subjects With PRNT50 Titer ≥1:10 At 7 Days After Last Active Vaccination","description":"Immune response was measured as the percentage of subjects with PRNT50 titer of ≥1:10 7 days after last active vaccination, ie, day 15 for the group that received the accelerated schedule and day 36 for the group that received the conventional schedule.\n\nAs per study design, this secondary immunogenicity outcome measure aimed to demonstrate non-inferiority of R/JE - Acc Vs JE - Conv.","populationDescription":"Analysis was done on the PP dataset.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentages of subjects","timeFrame":"Day 15 and day 36 (28 after last active vaccination)","groups":[{"id":"OG000","title":"R/JE - Acc","description":"Subjects received Rabies and JE vaccines, accelerated schedule, ie, Rabies vaccination on days 1, 4, and 8, and placebo on day 29 in the right arm or leg, and JE vaccination on days 1 and 8, and placebo on day 29 in the left arm."},{"id":"OG001","title":"JE - Conv","description":"Group Description Subjects received Rabies and JE vaccines, conventional schedule, i.e. Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg; and JE vaccination on day 1 and 29, and placebo on day 8 in the left arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99","lowerLimit":"96","upperLimit":"100"},{"groupId":"OG001","value":"100","lowerLimit":"92","upperLimit":"100"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Non-inferiority of the immune response of JE vaccine (administered concomitantly with Rabies vaccine) as given according to an accelerated schedule as compared to JE vaccine (administered alone) as given according to a conventional schedule at 7day after last active vaccine administration.","testedNonInferiority":true,"nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","nonInferiorityComment":"The immune response of accelerated schedule of the JE vaccine considered non-inferior to the conventional schedule if the lower bound of the two-sided 95% CI of the difference in the percentages of subjects with PRNT50 titer ≥1:10 measured 7 days after last active vaccine administration is greater than -10.","paramType":"Difference in percentages of subjects","paramValue":"-1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.1","ciUpperLimit":"6.2"}]},{"type":"SECONDARY","title":"Kinetics of Rabies Immune Response Measured as Percentage of Subjects With RVNA Concentration ≥0.5 IU/mL","description":"To evaluate the kinetics of antibody response to Rabies vaccine, the immunogenicity was measured as the percentage of subjects with RVNA concentrations ≥0.5 IU/mL on days 1, 8, 15, 36, 57, 91, 181, and 366.","populationDescription":"Analysis was done on the PP dataset.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentages of subjects","timeFrame":"Day 1, 8, 15, 36, 57, 91, 181 and Day 366","groups":[{"id":"OG000","title":"R/JE - Conv","description":"Subjects received Rabies and JE vaccines, conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg, and JE vaccination on day 1 and 29, and placebo on day 8 in the left arm."},{"id":"OG001","title":"R/JE - Acc","description":"Subjects received Rabies and JE vaccines, accelerated schedule, ie, Rabies vaccination on days 1, 4, and 8, and placebo on day 29 in the right arm or leg, and JE vaccination on days 1 and 8, and placebo on day 29 in the left arm."},{"id":"OG002","title":"R - Conv","description":"Subjects received Rabies vaccine, conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg, and placebo on days 1, 8 and 29 in the left arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"215"},{"groupId":"OG002","value":"218"}]}],"classes":[{"title":"Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"1","lowerLimit":"0.015","upperLimit":"3"},{"groupId":"OG001","value":"1","lowerLimit":"0","upperLimit":"3"},{"groupId":"OG002","value":"1","lowerLimit":"0","upperLimit":"4"}]}]},{"title":"Day 8 (N=161, 210, 213)","categories":[{"measurements":[{"groupId":"OG000","value":"4","lowerLimit":"2","upperLimit":"9"},{"groupId":"OG001","value":"16","lowerLimit":"11","upperLimit":"21"},{"groupId":"OG002","value":"4","lowerLimit":"2","upperLimit":"8"}]}]},{"title":"Day 15 (N=161, 209, 210)","categories":[{"measurements":[{"groupId":"OG000","value":"99","lowerLimit":"96","upperLimit":"100"},{"groupId":"OG001","value":"100","lowerLimit":"97","upperLimit":"100"},{"groupId":"OG002","value":"99","lowerLimit":"97","upperLimit":"100"}]}]},{"title":"Day 36 (N=157, 206, 207)","categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"98","upperLimit":"100"},{"groupId":"OG001","value":"99","lowerLimit":"96","upperLimit":"100"},{"groupId":"OG002","value":"100","lowerLimit":"97","upperLimit":"100"}]}]},{"title":"Day 57 (157, 204, 204)","categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"98","upperLimit":"100"},{"groupId":"OG001","value":"97","lowerLimit":"93","upperLimit":"99"},{"groupId":"OG002","value":"100","lowerLimit":"97","upperLimit":"100"}]}]},{"title":"Day 91 (N=152, 206, 204)","categories":[{"measurements":[{"groupId":"OG000","value":"99","lowerLimit":"95","upperLimit":"100"},{"groupId":"OG001","value":"85","lowerLimit":"79","upperLimit":"90"},{"groupId":"OG002","value":"98","lowerLimit":"95","upperLimit":"99"}]}]},{"title":"Day 181 (N= 155, 200, 202)","categories":[{"measurements":[{"groupId":"OG000","value":"88","lowerLimit":"82","upperLimit":"92"},{"groupId":"OG001","value":"75","lowerLimit":"68","upperLimit":"81"},{"groupId":"OG002","value":"89","lowerLimit":"84","upperLimit":"93"}]}]},{"title":"Day 366 (154, 199, 204)","categories":[{"measurements":[{"groupId":"OG000","value":"76","lowerLimit":"68","upperLimit":"82"},{"groupId":"OG001","value":"68","lowerLimit":"61","upperLimit":"74"},{"groupId":"OG002","value":"80","lowerLimit":"74","upperLimit":"85"}]}]}]},{"type":"SECONDARY","title":"Kinetics of Rabies Immune Response Measured as the RVNA GMCs","description":"To evaluate the kinetics of antibody response to Rabies vaccine, the immunogenicity was measured as the RVNA GMCs on days 1, 8, 15, 36, 57, 91, 181, and 366.","populationDescription":"Analysis was done on the PP dataset.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"IU/mL","timeFrame":"Day 1, 8, 15, 36, 57, 91, 181, and 366","groups":[{"id":"OG000","title":"R/JE - Conv","description":"Subjects received Rabies and JE vaccines, conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg, and JE vaccination on day 1 and 29, and placebo on day 8 in the left arm."},{"id":"OG001","title":"R/JE - Acc","description":"Subjects received Rabies and JE vaccines, accelerated schedule, ie, Rabies vaccination on days 1, 4, and 8, and placebo on day 29 in the right arm or leg, and JE vaccination on days 1 and 8, and placebo on day 29 in the left arm."},{"id":"OG002","title":"R - Conv","description":"Subjects received Rabies vaccine, conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg, and placebo on days 1, 8 and 29 in the left arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"215"},{"groupId":"OG002","value":"218"}]}],"classes":[{"title":"Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"0.052","lowerLimit":"0.048","upperLimit":"0.056"},{"groupId":"OG001","value":"0.053","lowerLimit":"0.049","upperLimit":"0.056"},{"groupId":"OG002","value":"0.054","lowerLimit":"0.05","upperLimit":"0.057"}]}]},{"title":"Day 8 (N=161, 210, 213)","categories":[{"measurements":[{"groupId":"OG000","value":"0.071","lowerLimit":"0.061","upperLimit":"0.084"},{"groupId":"OG001","value":"0.13","lowerLimit":"0.12","upperLimit":"0.16"},{"groupId":"OG002","value":"0.076","lowerLimit":"0.066","upperLimit":"0.088"}]}]},{"title":"Day 15 (N=161, 209, 210),","categories":[{"measurements":[{"groupId":"OG000","value":"21","lowerLimit":"17","upperLimit":"25"},{"groupId":"OG001","value":"26","lowerLimit":"22","upperLimit":"30"},{"groupId":"OG002","value":"24","lowerLimit":"20","upperLimit":"28"}]}]},{"title":"Day 36 (N=157, 206, 207)","categories":[{"measurements":[{"groupId":"OG000","value":"14","lowerLimit":"12","upperLimit":"17"},{"groupId":"OG001","value":"5.75","lowerLimit":"4.95","upperLimit":"6.67"},{"groupId":"OG002","value":"13","lowerLimit":"11","upperLimit":"15"}]}]},{"title":"Day 57 (N=157, 204, 204)","categories":[{"measurements":[{"groupId":"OG000","value":"10","lowerLimit":"8.72","upperLimit":"12"},{"groupId":"OG001","value":"3.01","lowerLimit":"2.59","upperLimit":"3.51"},{"groupId":"OG002","value":"9.66","lowerLimit":"8.31","upperLimit":"11"}]}]},{"title":"Day 91 (N=152, 206, 204)","categories":[{"measurements":[{"groupId":"OG000","value":"4.79","lowerLimit":"3.98","upperLimit":"5.76"},{"groupId":"OG001","value":"1.63","lowerLimit":"1.39","upperLimit":"1.91"},{"groupId":"OG002","value":"5.04","lowerLimit":"4.29","upperLimit":"5.91"}]}]},{"title":"Day 181 (N= 155, 200, 202)","categories":[{"measurements":[{"groupId":"OG000","value":"1.86","lowerLimit":"1.15","upperLimit":"2.3"},{"groupId":"OG001","value":"1","lowerLimit":"0.83","upperLimit":"1.21"},{"groupId":"OG002","value":"2.04","lowerLimit":"1.69","upperLimit":"2.46"}]}]},{"title":"Day 366 (N=154, 199, 204)","categories":[{"measurements":[{"groupId":"OG000","value":"0.93","lowerLimit":"0.75","upperLimit":"1.16"},{"groupId":"OG001","value":"0.82","lowerLimit":"0.67","upperLimit":"1"},{"groupId":"OG002","value":"1.14","lowerLimit":"0.94","upperLimit":"1.38"}]}]}]},{"type":"SECONDARY","title":"Kinetics of JE Immune Response Measured as Percentage of Subjects With PRNT50 Titers ≥1:10","description":"To evaluate the kinetics of antibody response to JE vaccine, the immunogenicity was measured as the percentage of subjects with PRNT50 titer ≥1:10 on days 1, 15, 22, 36, 57, 91, 181, and 366 (group that received JE vaccine as an accelerated schedule) and days 1, 36, 57, 181, and 366 (group that received JE vaccine as a conventional schedule).","populationDescription":"Analysis was done on the PP dataset.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentages of subjects","timeFrame":"Days 1, 15, 22, 36, 57, 91, 181 and 366","groups":[{"id":"OG000","title":"R/JE - Conv","description":"Subjects received Rabies and JE vaccines, conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg, and JE vaccination on day 1 and 29, and placebo on day 8 in the left arm."},{"id":"OG001","title":"R/JE - Acc","description":"Subjects received Rabies and JE vaccines, accelerated schedule, ie, Rabies vaccination on days 1, 4, and 8, and placebo on day 29 in the right arm or leg, and JE vaccination on days 1 and 8, and placebo on day 29 in the left arm."},{"id":"OG002","title":"JE - Conv","description":"Subjects received JE vaccine, conventional schedule, ie, placebo on days 1, 4, 8 and 29 in the right arm or leg, and JE vaccination on days 1 and 29 and placebo injection on day 8 in the left arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"215"},{"groupId":"OG002","value":"55"}]}],"classes":[{"title":"Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"1","lowerLimit":"0","upperLimit":"4"},{"groupId":"OG001","value":"6","lowerLimit":"3","upperLimit":"10"},{"groupId":"OG002","value":"9","lowerLimit":"3","upperLimit":"20"}]}]},{"title":"Day 15 (N=0, 209, 0)","categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Analysis was not performed in this group at this timepoint."},{"groupId":"OG001","value":"99","lowerLimit":"96","upperLimit":"100"},{"groupId":"OG002","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Analysis was not performed in this group at this timepoint."}]}]},{"title":"Day 22 (N=0, 208, 0)","categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Analysis was not performed in this group at this timepoint."},{"groupId":"OG001","value":"100","lowerLimit":"97","upperLimit":"100"},{"groupId":"OG002","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Analysis was not performed in this group at this timepoint."}]}]},{"title":"Day 36 (157, 206, 47)","categories":[{"measurements":[{"groupId":"OG000","value":"99","lowerLimit":"97","upperLimit":"100"},{"groupId":"OG001","value":"99","lowerLimit":"96","upperLimit":"100"},{"groupId":"OG002","value":"100","lowerLimit":"92","upperLimit":"100"}]}]},{"title":"Day 57 (N=157, 204, 49)","categories":[{"measurements":[{"groupId":"OG000","value":"100","lowerLimit":"98","upperLimit":"100"},{"groupId":"OG001","value":"98","lowerLimit":"95","upperLimit":"99"},{"groupId":"OG002","value":"100","lowerLimit":"93","upperLimit":"100"}]}]},{"title":"Day 91 (N=0, 206, 0)","categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Analysis was not performed in this group at this timepoint."},{"groupId":"OG001","value":"98","lowerLimit":"95","upperLimit":"99"},{"groupId":"OG002","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Analysis was not performed in this group at this timepoint."}]}]},{"title":"Day 181 (N=155, 200, 49)","categories":[{"measurements":[{"groupId":"OG000","value":"94","lowerLimit":"88","upperLimit":"97"},{"groupId":"OG001","value":"98","lowerLimit":"94","upperLimit":"99"},{"groupId":"OG002","value":"92","lowerLimit":"80","upperLimit":"98"}]}]},{"title":"Day 366 (N=154, 199, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"86","lowerLimit":"79","upperLimit":"91"},{"groupId":"OG001","value":"94","lowerLimit":"90","upperLimit":"97"},{"groupId":"OG002","value":"88","lowerLimit":"75","upperLimit":"95"}]}]}]},{"type":"SECONDARY","title":"Kinetics of JE Immune Response Measured as PRNT50 GMTs","description":"To evaluate the kinetics of antibody response to JE vaccine, the immunogenicity was measured as the PRNT50 GMTs on days 1, 15, 22, 36, 57, 91, 181, and 366 (group that received JE vaccine as an accelerated schedule) and days 1, 36, 57, 181, and 366 (group that received JE vaccine as a conventional schedule).","populationDescription":"Analysis was done on the PP dataset.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers","timeFrame":"Day 1, 15, 22, 36, 57, 91, 181, and 366 (accelerated schedule) and day 1, 36, 57, 181, and 366 (conventional schedule)","groups":[{"id":"OG000","title":"R/JE - Conv","description":"Subjects received Rabies and JE vaccines, conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg, and JE vaccination on day 1 and 29, and placebo on day 8 in the left arm."},{"id":"OG001","title":"R/JE - Acc","description":"Subjects received Rabies and JE vaccines, accelerated schedule, ie, Rabies vaccination on days 1, 4, and 8, and placebo on day 29 in the right arm or leg, and JE vaccination on days 1 and 8, and placebo on day 29 in the left arm."},{"id":"OG002","title":"JE - Conv","description":"Subjects received JE vaccine, conventional schedule, ie, placebo on days 1, 4, 8 and 29 in the right arm or leg, and JE vaccination on days 1 and 29 and placebo injection on day 8 in the left arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"215"},{"groupId":"OG002","value":"55"}]}],"classes":[{"title":"Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"5.13","lowerLimit":"4.84","upperLimit":"5.43"},{"groupId":"OG001","value":"5.63","lowerLimit":"5.35","upperLimit":"5.92"},{"groupId":"OG002","value":"5.73","lowerLimit":"5.2","upperLimit":"6.33"}]}]},{"title":"Day 15 (N=0, 209, 0)","categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Analysis was not performed in this group at this timepoint."},{"groupId":"OG001","value":"715","lowerLimit":"608","upperLimit":"842"},{"groupId":"OG002","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Analysis was not performed in this group at this timepoint."}]}]},{"title":"Day 22 (0, 208, 0)","categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Analysis was not performed in this group at this timepoint."},{"groupId":"OG001","value":"1255","lowerLimit":"1068","upperLimit":"1475"},{"groupId":"OG002","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Analysis was not performed in this group at this timepoint."}]}]},{"title":"Day 36 (N=157, 206, 47)","categories":[{"measurements":[{"groupId":"OG000","value":"292","lowerLimit":"247","upperLimit":"346"},{"groupId":"OG001","value":"690","lowerLimit":"595","upperLimit":"801"},{"groupId":"OG002","value":"376","lowerLimit":"277","upperLimit":"510"}]}]},{"title":"Day 57 (N= 157, 204, 49)","categories":[{"measurements":[{"groupId":"OG000","value":"299","lowerLimit":"254","upperLimit":"352"},{"groupId":"OG001","value":"372","lowerLimit":"322","upperLimit":"430"},{"groupId":"OG002","value":"337","lowerLimit":"252","upperLimit":"451"}]}]},{"title":"Day 91 (N=0, 206, 0)","categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Analysis was not performed in this group at this timepoint."},{"groupId":"OG001","value":"228","lowerLimit":"192","upperLimit":"272"},{"groupId":"OG002","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Analysis was not performed in this group at this timepoint."}]}]},{"title":"Day 181 (N=155, 200, 49)","categories":[{"measurements":[{"groupId":"OG000","value":"63","lowerLimit":"53","upperLimit":"75"},{"groupId":"OG001","value":"151","lowerLimit":"130","upperLimit":"176"},{"groupId":"OG002","value":"64","lowerLimit":"47","upperLimit":"87"}]}]},{"title":"Day 366 (N=154, 199, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"39","lowerLimit":"33","upperLimit":"47"},{"groupId":"OG001","value":"117","lowerLimit":"100","upperLimit":"137"},{"groupId":"OG002","value":"39","lowerLimit":"28","upperLimit":"54"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Who Reported Solicited Local Adverse Events After Each Rabies Vaccination","description":"Safety was assessed as the number of subjects who reported solicited local adverse events (AEs) after each rabies vaccination given according to accelerated or conventional schedule as follows: from day 1 through day 7 (vaccination on day 1; all Rabies groups), day 4 through day 10 (vaccination on day 4; in R/JE - Acc group only), day 8 through day 14 (vaccination on day 8; all Rabies groups), or day 29 through day 35 (vaccination on day 29; R/JE - Conv and R - Conv groups).","populationDescription":"Analysis was done on the solicited safety set, i.e. the subjects in the exposed population who provided postvaccination solicited safety data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Number of subjects","timeFrame":"Day 1 through day 7 after each vaccination (on day 1, 4, 8 and 29)","groups":[{"id":"OG000","title":"R/JE - Conv","description":"Subjects received Rabies and JE vaccines, conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg, and JE vaccination on day 1 and 29, and placebo on day 8 in the left arm."},{"id":"OG001","title":"R/JE - Acc","description":"Subjects received Rabies and JE vaccines, accelerated schedule, ie, Rabies vaccination on days 1, 4, and 8, and placebo on day 29 in the right arm or leg, and JE vaccination on days 1 and 8, and placebo on day 29 in the left arm."},{"id":"OG002","title":"R - Conv","description":"Subjects received Rabies vaccine, conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg, and placebo on days 1, 8 and 29 in the left arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"217"},{"groupId":"OG002","value":"220"}]}],"classes":[{"title":"Erythema (day 1 to 7)","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"28"}]}]},{"title":"Induration (day 1 to 7)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"11"}]}]},{"title":"Pain (day 1 to 7)","categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"69"},{"groupId":"OG002","value":"72"}]}]},{"title":"Erythema (day 4 to 10)","categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"Subjects in this group received placebo at day 4"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"NA","comment":"Subjects in this group received placebo at day 4"}]}]},{"title":"Induration (day 4 to 10)","categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"Subjects in this group received placebo at day 4"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"NA","comment":"Subjects in this group received placebo at day 4"}]}]},{"title":"Pain (day 4 to 10)","categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"Subjects in this group received placebo at day 4"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"NA","comment":"Subjects in this group received placebo at day 4"}]}]},{"title":"Erythema (day 8 to 14)","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"29"}]}]},{"title":"Induration (day 8 to 14)","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"17"}]}]},{"title":"Pain (day 8 to 14)","categories":[{"measurements":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"90"}]}]},{"title":"Erythema (day 29 to 35)","categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"NA","comment":"Subjects in this group received placebo at day 29"},{"groupId":"OG002","value":"45"}]}]},{"title":"Induration (day 29 to 35)","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"NA","comment":"Subjects in this group received placebo at day 29"},{"groupId":"OG002","value":"32"}]}]},{"title":"Pain (day 29 to 35)","categories":[{"measurements":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"NA","comment":"Subjects in this group received placebo at day 29"},{"groupId":"OG002","value":"87"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Who Reported Solicited Local AEs After Each JE Vaccination","description":"Safety was assessed as the number of subjects who reported solicited local AEs after each JE vaccination given according to accelerated or conventional schedule as follow: from day 1 through day 7 (vaccination on day 1; all JE groups), day 8 through day 14 (vaccination on day 8; R/JE - Acc group only), or day 29 through day 35 (vaccination on day 29; R/JE - Con and JE - Conv groups).","populationDescription":"Analysis was done on the solicited safety set.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Number of subjects","timeFrame":"Day 1 through day 7 after each vaccination (on day 1, 8 and 29)","groups":[{"id":"OG000","title":"R/JE - Conv","description":"Subjects received Rabies and JE vaccines, conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg, and JE vaccination on day 1 and 29, and placebo on day 8 in the left arm."},{"id":"OG001","title":"R/JE - Acc","description":"Subjects received Rabies and JE vaccines, accelerated schedule, ie, Rabies vaccination on days 1, 4, and 8, and placebo on day 29 in the right arm or leg, and JE vaccination on days 1 and 8, and placebo on day 29 in the left arm."},{"id":"OG002","title":"JE - Conv","description":"Subjects received JE vaccine, conventional schedule, ie, placebo on days 1, 4, 8 and 29 in the right arm or leg, and JE vaccination on days 1 and 29 and placebo injection on day 8 in the left arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"217"},{"groupId":"OG002","value":"56"}]}],"classes":[{"title":"Erythema (day 1 to 7)","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"6"}]}]},{"title":"Induration (day 1 to 7)","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"5"}]}]},{"title":"Pain (day 1 to 7)","categories":[{"measurements":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"102"},{"groupId":"OG002","value":"26"}]}]},{"title":"Erythema (day 8 to 14)","categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"Subjects in this group didn't receive JE vaccination on day 8."},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"NA","comment":"Subjects in this group didn't receive JE vaccination on day 8."}]}]},{"title":"Induration (day 8 to 14)","categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"Subjects in this group didn't receive JE vaccination on day 8."},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"NA","comment":"Subjects in this group didn't receive JE vaccination on day 8."}]}]},{"title":"Pain (day 8 to 14)","categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"Subjects in this group didn't receive JE vaccination on day 8."},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"NA","comment":"Subjects in this group didn't receive JE vaccination on day 8."}]}]},{"title":"Erythema (day 29 to 35)","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"NA","comment":"Subjects in this group didn't receive JE vaccination on day 29."},{"groupId":"OG002","value":"5"}]}]},{"title":"Induration (day 29 to 35)","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"NA","comment":"Subjects in this group didn't receive JE vaccination on day 29."},{"groupId":"OG002","value":"4"}]}]},{"title":"Pain (day 29 to 35)","categories":[{"measurements":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"NA","comment":"Subjects in this group didn't receive JE vaccination on day 29."},{"groupId":"OG002","value":"12"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Who Reported Solicited Local AEs After Each Placebo Injection","description":"Safety was assessed as the number of subjects who reported solicited local AEs after each placebo injection given according to accelerated and conventional schedule as follow: from day 1 through day 7 (injection on day 1; R - Conv and JE - Conv groups), day 4 through day 10 (injection on day 4; in R/JE - Conv, R - Conv and JE - Conv groups), day 8 through day 14 (injection on day 8; in R/JE - Conv, R - Conv and JE - Conv groups), and day 29 through day 35 (injection on day 29; R/JE - Acc, R - Con and JE - Conv groups).","populationDescription":"Analysis was done on the solicited safety set.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Number of Subjects","timeFrame":"Day 1 through day 7 after each injection (day 1, 4, 8 and 29)","groups":[{"id":"OG000","title":"R/JE - Conv","description":"Subjects received Rabies and JE vaccines, conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg, and JE vaccination on day 1 and 29, and placebo on day 8 in the left arm."},{"id":"OG001","title":"R/JE - Acc","description":"Subjects received Rabies and JE vaccines, accelerated schedule, ie, Rabies vaccination on days 1, 4, and 8, and placebo on day 29 in the right arm or leg, and JE vaccination on days 1 and 8, and placebo on day 29 in the left arm."},{"id":"OG002","title":"R - Conv","description":"Subjects received Rabies vaccine, conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg, and placebo on days 1, 8 and 29 in the left arm."},{"id":"OG003","title":"JE - Conv","description":"Subjects received JE vaccine, conventional schedule, ie, placebo on days 1, 4, 8 and 29 in the right arm or leg, and JE vaccination on days 1 and 29 and placebo injection on day 8 in the left arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"213"},{"groupId":"OG002","value":"220"},{"groupId":"OG003","value":"56"}]}],"classes":[{"title":"Erythema (day 1 to 7)","categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"Subjects in this group didn't receive placebo at day 1."},{"groupId":"OG001","value":"NA","comment":"Subjects in this group didn't receive placebo at day 1."},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"3"}]}]},{"title":"Induration (day 1 to 7)","categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"Subjects in this group didn't receive placebo at day 1."},{"groupId":"OG001","value":"NA","comment":"Subjects in this group didn't receive placebo at day 1."},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"}]}]},{"title":"Pain (day 1 to 7)","categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"Subjects in this group didn't receive placebo at day 1."},{"groupId":"OG001","value":"NA","comment":"Subjects in this group didn't receive placebo at day 1."},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"7"}]}]},{"title":"Erythema (day 4 to 10)","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"NA","comment":"Subjects in this group didn't receive placebo at day 4."},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"3"}]}]},{"title":"Induration (day 4 to 10)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"NA","comment":"Subjects in this group didn't receive placebo at day 4."},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"2"}]}]},{"title":"Pain (day 4 to 10)","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"NA","comment":"Subjects in this group didn't receive placebo at day 4."},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"3"}]}]},{"title":"Erythema (day 8 to 14)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"NA","comment":"Subjects in this group didn't receive placebo at day 8."},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"4"}]}]},{"title":"Erythema (day 8 to 14 after 2nd Placebo dose)","categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"Subjects in this group received only 1 dose of placebo at day 8."},{"groupId":"OG001","value":"NA","comment":"Subjects in this group didn't receive placebo at day 8."},{"groupId":"OG002","value":"NA","comment":"Subjects in this group received only 1 dose of placebo at day 8."},{"groupId":"OG003","value":"3"}]}]},{"title":"Induration (day 8 to 14)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"NA","comment":"Subjects in this group didn't receive placebo at day 8."},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"1"}]}]},{"title":"Induration (day 8 to 14 after 2nd Placebo dose)","categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"Subjects in this group received only 1 dose of placebo at day 8."},{"groupId":"OG001","value":"NA","comment":"Subjects in this group didn't receive placebo at day 8."},{"groupId":"OG002","value":"NA","comment":"Subjects in this group received only 1 dose of placebo at day 8."},{"groupId":"OG003","value":"1"}]}]},{"title":"Pain (day 8 to 14)","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"NA","comment":"Subjects in this group didn't receive placebo at day 8."},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"3"}]}]},{"title":"Pain (day 8 to 14 after 2nd Placebo dose)","categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"Subjects in this group received only 1 dose of placebo at day 8."},{"groupId":"OG001","value":"NA","comment":"Subjects in this group didn't receive placebo at day 8."},{"groupId":"OG002","value":"NA","comment":"Subjects in this group received only 1 dose of placebo at day 8."},{"groupId":"OG003","value":"5"}]}]},{"title":"Erythema (day 29 to 35)","categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"Subjects in this group didn't receive placebo at day 29."},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"3"}]}]},{"title":"Erythema (day 29 to 35 after 2nd Placebo dose)","categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"Subjects in this group didn't receive placebo at day 29."},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"NA","comment":"Subjects in this group received only 1 dose of placebo at day 29."},{"groupId":"OG003","value":"NA","comment":"Subjects in this group received only 1 dose of placebo at day 29."}]}]},{"title":"Induration (day 29 to 35)","categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"Subjects in this group didn't receive placebo at day 29."},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"1"}]}]},{"title":"Induration (day 29 to 35 after 2nd Placebo dose)","categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"Subjects in this group didn't receive placebo at day 29."},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"NA","comment":"Subjects in this group received only 1 dose of placebo at day 29."},{"groupId":"OG003","value":"NA","comment":"Subjects in this group received only 1 dose of placebo at day 29."}]}]},{"title":"Pain (day 29 to 35)","categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"Subjects in this group didn't receive placebo at day 29."},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"3"}]}]},{"title":"Pain (day 29 to 35 after 2nd Placebo dose)","categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"Subjects in this group didn't receive placebo at day 29."},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"NA","comment":"Subjects in this group received only 1 dose of placebo at day 29."},{"groupId":"OG003","value":"NA","comment":"Subjects in this group received only 1 dose of placebo at day 29."}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Who Reported Solicited Systemic AEs and Other Indicators of Reactogenicity After Each Vaccination","description":"Safety was assessed as the number of subjects who reported solicited systemic AEs and other indicators of reactogenicity after each vaccination given according to accelerated and conventional schedule.","populationDescription":"Analysis was done on the solicited safety set.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Number of Subjects","timeFrame":"Day 1 through day 7 after each vaccination (day 1, 4, 8 and 29)","groups":[{"id":"OG000","title":"R/JE - Conv","description":"Subjects received Rabies and JE vaccines, conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg, and JE vaccination on day 1 and 29, and placebo on day 8 in the left arm."},{"id":"OG001","title":"R/JE - Acc","description":"Subjects received Rabies and JE vaccines, accelerated schedule, ie, Rabies vaccination on days 1, 4, and 8, and placebo on day 29 in the right arm or leg, and JE vaccination on days 1 and 8, and placebo on day 29 in the left arm."},{"id":"OG002","title":"R - Conv","description":"Subjects received Rabies vaccine, conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg, and placebo on days 1, 8 and 29 in the left arm."},{"id":"OG003","title":"JE - Conv","description":"Subjects received JE vaccine, conventional schedule, ie, placebo on days 1, 4, 8 and 29 in the right arm or leg, and JE vaccination on days 1 and 29 and placebo injection on day 8 in the left arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"217"},{"groupId":"OG002","value":"220"},{"groupId":"OG003","value":"56"}]}],"classes":[{"title":"Fatigue (day 1 to 7)","categories":[{"measurements":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"46"},{"groupId":"OG003","value":"16"}]}]},{"title":"Headache (day 1 to 7)","categories":[{"measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"46"},{"groupId":"OG002","value":"38"},{"groupId":"OG003","value":"14"}]}]},{"title":"Myalgia (day 1 to 7)","categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"7"}]}]},{"title":"Arthralgia (day 1 to 7)","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"1"}]}]},{"title":"Loss of Appetite (day1 to day 7)","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"6"}]}]},{"title":"Nausea (day1 to day 7)","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"4"}]}]},{"title":"Body temperature (≥38 °C, day 1 to day 7)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}]}]},{"title":"Analgesic/Antipyretic used (day 1 to day 7)","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"3"}]}]},{"title":"Fatigue (day 4 to 10)","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"5"}]}]},{"title":"Headache (day 4 to 10)","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"3"}]}]},{"title":"Myalgia (day 4 to 10)","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"1"}]}]},{"title":"Arthralgia (day 4 to 10)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"0"}]}]},{"title":"Loss of Appetite (day4 to day 10)","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"2"}]}]},{"title":"Nausea (day4 to day 10)","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"0"}]}]},{"title":"Body temperature (≥38 °C, day 4 to day 10)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"}]}]},{"title":"Analgesic/Antipyretic used (day 4 to 10)","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"2"}]}]},{"title":"Fatigue (day 8 to 14)","categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"47"},{"groupId":"OG002","value":"47"},{"groupId":"OG003","value":"6"}]}]},{"title":"Headache (day 8 to 14)","categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"43"},{"groupId":"OG002","value":"41"},{"groupId":"OG003","value":"3"}]}]},{"title":"Myalgia (day 8 to 14)","categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"41"},{"groupId":"OG002","value":"38"},{"groupId":"OG003","value":"1"}]}]},{"title":"Arthralgia (day 8 to 14)","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"1"}]}]},{"title":"Loss of Appetite (day8 to day 14)","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"2"}]}]},{"title":"Nausea (day8 to day 14)","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"2"}]}]},{"title":"Body temperature (≥38 °C, day 8 to 14)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"0"}]}]},{"title":"Analgesic/Antipyretic used (day 8 to 14)","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"2"}]}]},{"title":"Fatigue (day 29 to 35)","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"3"}]}]},{"title":"Headache (day 29 to 35)","categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"40"},{"groupId":"OG003","value":"4"}]}]},{"title":"Myalgia (day 29 to 35)","categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"2"}]}]},{"title":"Arthralgia (day 29 to 35)","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"1"}]}]},{"title":"Body temperature (≥38 °C, day 29 to day 35)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}]},{"title":"Analgesic/Antipyretic used (day 29 to day 35)","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"3"}]}]},{"title":"Loss if appetite (day 29 to day 25)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"2"}]}]},{"title":"nausea (day29 to day 25)","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"2"}]}]}]},{"type":"SECONDARY","title":"Numbers of Subjects Reporting Unsolicited AEs After Any Vaccination From Day 1 Through Day 57","description":"Safety was assessed as the number of subjects who reported unsolicited AEs after any vaccination given according to accelerated and conventional schedule.","populationDescription":"Analysis was done on the unsolicited safety set, ie, the subjects in the exposed population who provided postvaccination unsolicited safety data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Number of subjects","timeFrame":"Day 1 through Day 57","groups":[{"id":"OG000","title":"R/JE - Conv","description":"Subjects received Rabies and JE vaccines, conventional schedule, i.e. Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg; and JE vaccination on day 1 and 29, and placebo on day 8 in the left arm."},{"id":"OG001","title":"R/JE - Acc","description":"Subjects received Rabies and JE vaccines, accelerated schedule, i.e. Rabies vaccination on days 1, 4, and 8, and placebo on day 29 in the right arm or leg; and JE vaccination on days 1 and 8, and placebo on day 29 in the left arm."},{"id":"OG002","title":"R - Conv","description":"Subjects received Rabies vaccine, conventional schedule, i.e. Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg; and placebo on days 1, 8 and 29 in the left arm."},{"id":"OG003","title":"JE - Conv","description":"Subjects received JE vaccine, conventional schedule, i.e. placebo on days 1, 4, 8 and 29 in the right arm or leg; and JE vaccination on days 1 and 29 and placebo injection on day 8 in the left arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"217"},{"groupId":"OG002","value":"220"},{"groupId":"OG003","value":"56"}]}],"classes":[{"title":"Any AE","categories":[{"measurements":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"108"},{"groupId":"OG002","value":"110"},{"groupId":"OG003","value":"29"}]}]},{"title":"SAEs","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"}]}]},{"title":"AEs leading to premature withdrawal","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Solicited AEs were collected for 7 days after each vaccination. All unsolicited AEs, serious adverse events (SAEs), AEs leading to study and/or treatment withdrawal were collected through day 57. From day 57 to day 366 vaccine-related SAEs were collected.","description":"Solicited adverse events were collected by systematic assessment, unsolicited AEs by non-systematic assessment. SAEs analysis was done one the unsolicited safety set, other AEs analysis was done on the overall safety set.","eventGroups":[{"id":"EG000","title":"R/JE - Conv","description":"Subjects received Rabies and JE vaccines, conventional schedule, i.e. Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg; and JE vaccination on day 1 and 29, and placebo on day 8 in the left arm.","seriousNumAffected":2,"seriousNumAtRisk":166,"otherNumAffected":138,"otherNumAtRisk":166},{"id":"EG001","title":"R/JE - Acc","description":"Subjects received Rabies and JE vaccines, accelerated schedule, i.e. Rabies vaccination on days 1, 4, and 8, and placebo on day 29 in the right arm or leg; and JE vaccination on days 1 and 8, and placebo on day 29 in the left arm.","seriousNumAffected":3,"seriousNumAtRisk":217,"otherNumAffected":186,"otherNumAtRisk":217},{"id":"EG002","title":"R - Conv","description":"Subjects received Rabies vaccine, conventional schedule, i.e. Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg; and placebo on days 1, 8 and 29 in the left arm.","seriousNumAffected":2,"seriousNumAtRisk":220,"otherNumAffected":185,"otherNumAtRisk":220},{"id":"EG003","title":"JE - Conv","description":"Subjects received JE vaccine, conventional schedule, i.e. placebo on days 1, 4, 8 and 29 in the right arm or leg; and JE vaccination on days 1 and 29 and placebo injection on day 8 in the left arm.","seriousNumAffected":3,"seriousNumAtRisk":56,"otherNumAffected":45,"otherNumAtRisk":56}],"seriousEvents":[{"term":"ATRIAL FIBRILLATION","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (17.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":217},{"groupId":"EG002","numAffected":1,"numAtRisk":220},{"groupId":"EG003","numAffected":0,"numAtRisk":56}]},{"term":"TACHYCARDIA","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (17.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":217},{"groupId":"EG002","numAffected":1,"numAtRisk":220},{"groupId":"EG003","numAffected":0,"numAtRisk":56}]},{"term":"EYELID OEDEMA","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (17.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":217},{"groupId":"EG002","numAffected":0,"numAtRisk":220},{"groupId":"EG003","numAffected":1,"numAtRisk":56}]},{"term":"PANCREATITIS ACUTE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (17.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":1,"numAtRisk":217},{"groupId":"EG002","numAffected":0,"numAtRisk":220},{"groupId":"EG003","numAffected":0,"numAtRisk":56}]},{"term":"CHOLECYSTITIS","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (17.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":217},{"groupId":"EG002","numAffected":0,"numAtRisk":220},{"groupId":"EG003","numAffected":1,"numAtRisk":56}]},{"term":"CHOLELITHIASIS","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (17.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":217},{"groupId":"EG002","numAffected":0,"numAtRisk":220},{"groupId":"EG003","numAffected":1,"numAtRisk":56}]},{"term":"HUMERUS FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (17.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":217},{"groupId":"EG002","numAffected":0,"numAtRisk":220},{"groupId":"EG003","numAffected":0,"numAtRisk":56}]},{"term":"MENISCUS INJURY","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (17.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":1,"numAtRisk":217},{"groupId":"EG002","numAffected":0,"numAtRisk":220},{"groupId":"EG003","numAffected":0,"numAtRisk":56}]},{"term":"OVARIAN GERM CELL TERATOMA BENIGN","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (17.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":1,"numAtRisk":217},{"groupId":"EG002","numAffected":0,"numAtRisk":220},{"groupId":"EG003","numAffected":0,"numAtRisk":56}]},{"term":"SYNCOPE","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (17.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":217},{"groupId":"EG002","numAffected":1,"numAtRisk":220},{"groupId":"EG003","numAffected":0,"numAtRisk":56}]},{"term":"ALCOHOL WITHDRAWAL SYNDROME","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (17.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":217},{"groupId":"EG002","numAffected":0,"numAtRisk":220},{"groupId":"EG003","numAffected":1,"numAtRisk":56}]},{"term":"DEPRESSION","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (17.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":217},{"groupId":"EG002","numAffected":0,"numAtRisk":220},{"groupId":"EG003","numAffected":0,"numAtRisk":56}]},{"term":"PRURITUS GENERALISED","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (17.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":217},{"groupId":"EG002","numAffected":0,"numAtRisk":220},{"groupId":"EG003","numAffected":1,"numAtRisk":56}]}],"otherEvents":[{"term":"NAUSEA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (17.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":166},{"groupId":"EG001","numAffected":31,"numAtRisk":217},{"groupId":"EG002","numAffected":35,"numAtRisk":220},{"groupId":"EG003","numAffected":9,"numAtRisk":56}]},{"term":"FATIGUE","organSystem":"General disorders","sourceVocabulary":"MedDRA (17.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":54,"numAtRisk":166},{"groupId":"EG001","numAffected":93,"numAtRisk":217},{"groupId":"EG002","numAffected":84,"numAtRisk":220},{"groupId":"EG003","numAffected":19,"numAtRisk":56}]},{"term":"INJECTION SITE ERYTHEMA","organSystem":"General disorders","sourceVocabulary":"MedDRA (17.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":48,"numAtRisk":166},{"groupId":"EG001","numAffected":73,"numAtRisk":217},{"groupId":"EG002","numAffected":85,"numAtRisk":220},{"groupId":"EG003","numAffected":13,"numAtRisk":56}]},{"term":"INJECTION SITE INDURATION","organSystem":"General disorders","sourceVocabulary":"MedDRA (17.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":166},{"groupId":"EG001","numAffected":43,"numAtRisk":217},{"groupId":"EG002","numAffected":48,"numAtRisk":220},{"groupId":"EG003","numAffected":10,"numAtRisk":56}]},{"term":"INJECTION SITE PAIN","organSystem":"General disorders","sourceVocabulary":"MedDRA (17.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":115,"numAtRisk":166},{"groupId":"EG001","numAffected":146,"numAtRisk":217},{"groupId":"EG002","numAffected":131,"numAtRisk":220},{"groupId":"EG003","numAffected":31,"numAtRisk":56}]},{"term":"NASOPHARYNGITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (17.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":166},{"groupId":"EG001","numAffected":33,"numAtRisk":217},{"groupId":"EG002","numAffected":32,"numAtRisk":220},{"groupId":"EG003","numAffected":7,"numAtRisk":56}]},{"term":"DECREASED APPETITE","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (17.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":166},{"groupId":"EG001","numAffected":24,"numAtRisk":217},{"groupId":"EG002","numAffected":27,"numAtRisk":220},{"groupId":"EG003","numAffected":9,"numAtRisk":56}]},{"term":"ARTHRALGIA","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (17.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":166},{"groupId":"EG001","numAffected":29,"numAtRisk":217},{"groupId":"EG002","numAffected":31,"numAtRisk":220},{"groupId":"EG003","numAffected":3,"numAtRisk":56}]},{"term":"MYALGIA","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (17.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":50,"numAtRisk":166},{"groupId":"EG001","numAffected":75,"numAtRisk":217},{"groupId":"EG002","numAffected":60,"numAtRisk":220},{"groupId":"EG003","numAffected":10,"numAtRisk":56}]},{"term":"HEADACHE","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (17.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":63,"numAtRisk":166},{"groupId":"EG001","numAffected":94,"numAtRisk":217},{"groupId":"EG002","numAffected":95,"numAtRisk":220},{"groupId":"EG003","numAffected":19,"numAtRisk":56}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"LTE60","restrictiveAgreement":true},"pointOfContact":{"title":"Posting Director","organization":"Novartis Vaccines","email":"RegistryContactVaccinesUS@novartis.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D011818","term":"Rabies"},{"id":"D004672","term":"Encephalitis, Japanese"}],"ancestors":[{"id":"D018353","term":"Rhabdoviridae Infections"},{"id":"D018701","term":"Mononegavirales Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D007239","term":"Infections"},{"id":"D004671","term":"Encephalitis, Arbovirus"},{"id":"D018792","term":"Encephalitis, Viral"},{"id":"D020805","term":"Central Nervous System Viral Diseases"},{"id":"D002494","term":"Central Nervous System Infections"},{"id":"D000069544","term":"Infectious Encephalitis"},{"id":"D001102","term":"Arbovirus Infections"},{"id":"D000079426","term":"Vector Borne Diseases"},{"id":"D000096724","term":"Mosquito-Borne Diseases"},{"id":"D018177","term":"Flavivirus Infections"},{"id":"D018178","term":"Flaviviridae Infections"},{"id":"D004660","term":"Encephalitis"},{"id":"D001927","term":"Brain Diseases"},{"id":"D002493","term":"Central Nervous System Diseases"},{"id":"D009422","term":"Nervous System Diseases"},{"id":"D000090862","term":"Neuroinflammatory Diseases"}]}},"hasResults":true}